Fused tricyclic compounds as inhibitors of tumor necrosis...

Details Fused tricyclic compounds as inhibitors of tumor necrosis... Fused tricyclic compounds as inhibitors of tumor necrosis...

2011-06-21

2011-06-21

Solola, Taofiq A (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07964631

ABSTRACT:
Compounds of formula 1:are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14or NR15; where R13is H, alkyl; R14is H, OH, OR13or OCOR13; R15is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7and R8are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.

REFERENCES:
patent: 4431808 (1984-02-01), Protiva et al.
patent: 5036067 (1991-07-01), Girard et al.
patent: 2003/0171585 (2003-09-01), Scott et al.
patent: 1 505 085 (1978-03-01), None
patent: 8 119920 (1996-05-01), None
patent: 90 40662 (1997-02-01), None
patent: 11 130772 (1999-05-01), None
patent: WO 96/31497 (1996-10-01), None
Palladino et al., “Anti-TNF-αTherapies: The Next Generation.”Nature Reviews2(2003): 736-746.
Yale et al., “Novel Polycyclic Heterocycles, Derivatives of 5,11-Dihydrodibenz[b,e][1,4]oxazepine and 5,11-Dihydrodibenzo[b,e][1,4]thiazepine.”Journal of Medicinal Chemistry13, 4(1970): 713-722.
Oda et al., “Clevage of Vinyl Carbon-Silicon Bond with Tetrabutylammonium Flouride.”Tetrahedron41(1985): 3257-3268.
Baruah, Robindra N., “An efficient system: Cobalt(II) chloride hexahydrate-zinc-dimethylformamide-water for reduction of nitroarenes.”Indian Journal of Chemistry33B (1994): 758.
Overman et al., “The Reduction of Aryl Disulfides with Triphenyl-phosphine and Water.”Synthesis(1974): 59-60.
Ackrell et al., “Synthesis and Antiinflammatory Activity of 6,11-Dihydro-11-oxodibenzo[b,e]thiepinalkanoic Acids and Related Compounds.”Journal of Medicinal Chemistry21,10(1978): 1035-1044.
Wilson et al., “A convenient human whole blood culture system for studying the regulation of tumour necrosis factor release by bacterial lipopolysaccharide.”Journal of Immunological Methods139(1991): 233-240.
Henry et al., “Potent Inhibitors of the Map Kinase p38.”Bioorganic&Medicinal Chemistry Letters8(1998): 3335-3340.
Brennan et al., “Inhibitory Effect of TNFα Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis.”The Lancet(1989): 244-247.
Fukuda et al., “A novel dual regulator of tumor necrosis factor-α and interleukin-10 protects mice from endotoxin-induced shock.”European Journal of Pharmacology391(2000): 317-320.
Sindelar et al., “Butaclamol-Like Neuroleptic Agents: Synthesis of 1-(11H-Dibenz[b,f]-1,4-Oxathiepin-11-YL)Methyl-4-Isobutylpiperdin-4-OL and of Some Related Compounds.”Collection of Czechoslocak Chemical Communications50,7(1985): 1484-1497.
Sindelar et al., “Tricyclic Psychotropic Agents Containing Two Chalcogen Atoms in the Central Ring: Derivatives of 11H-Dibenz[b,f]-1,4-Oxathiepin.”Collection of Czechoslovak Chemical Communications47(1982): 967-983.
PCT International Search Report for PCT/IB2005/053654, Jun. 6, 2006.

Affiliated with

Also associated with

Rating

Fused tricyclic compounds as inhibitors of tumor necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused tricyclic compounds as inhibitors of tumor necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused tricyclic compounds as inhibitors of tumor necrosis... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2708013